ATE334656T1 - Flüssige pharmazeutische zusammensetzung - Google Patents

Flüssige pharmazeutische zusammensetzung

Info

Publication number
ATE334656T1
ATE334656T1 AT02727834T AT02727834T ATE334656T1 AT E334656 T1 ATE334656 T1 AT E334656T1 AT 02727834 T AT02727834 T AT 02727834T AT 02727834 T AT02727834 T AT 02727834T AT E334656 T1 ATE334656 T1 AT E334656T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
liquid
composition
pharmaceutical
Prior art date
Application number
AT02727834T
Other languages
English (en)
Inventor
Neema Mahesh Kulkarni
Michael Schneider
Steven Bernard Silbering
Hans Richard Meyer-Wonnay
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE334656(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE334656T1 publication Critical patent/ATE334656T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT02727834T 2001-05-25 2002-04-29 Flüssige pharmazeutische zusammensetzung ATE334656T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29383201P 2001-05-25 2001-05-25
US34373301P 2001-10-25 2001-10-25

Publications (1)

Publication Number Publication Date
ATE334656T1 true ATE334656T1 (de) 2006-08-15

Family

ID=26968180

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02727834T ATE334656T1 (de) 2001-05-25 2002-04-29 Flüssige pharmazeutische zusammensetzung

Country Status (43)

Country Link
US (2) US20020198261A1 (de)
EP (1) EP1395242B1 (de)
JP (1) JP2004534764A (de)
KR (1) KR100582963B1 (de)
CN (1) CN100346779C (de)
AP (1) AP1815A (de)
AR (1) AR033922A1 (de)
AT (1) ATE334656T1 (de)
AU (1) AU2002258026B2 (de)
BG (1) BG108376A (de)
BR (1) BR0209973A (de)
CA (1) CA2446574C (de)
CR (1) CR7150A (de)
CY (1) CY1105147T1 (de)
CZ (1) CZ299755B6 (de)
DE (1) DE60213592T2 (de)
DK (1) DK1395242T3 (de)
DO (1) DOP2002000403A (de)
EA (1) EA008087B1 (de)
EE (1) EE200300587A (de)
EG (1) EG24078A (de)
ES (1) ES2265040T3 (de)
GE (1) GEP20053620B (de)
HR (1) HRP20030833B1 (de)
HU (1) HUP0401366A2 (de)
IL (1) IL158359A0 (de)
IS (1) IS2428B (de)
MA (1) MA27026A1 (de)
MX (1) MXPA03009392A (de)
MY (1) MY128615A (de)
NO (1) NO20035200D0 (de)
NZ (1) NZ529173A (de)
OA (1) OA12604A (de)
PA (1) PA8545901A1 (de)
PE (1) PE20030087A1 (de)
PL (1) PL366384A1 (de)
PT (1) PT1395242E (de)
RS (1) RS87203A (de)
SI (1) SI1395242T1 (de)
SK (1) SK286227B6 (de)
SV (1) SV2003001053A (de)
WO (1) WO2002094220A1 (de)
ZA (1) ZA200308393B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2200184T7 (es) 1996-07-24 2015-02-10 Warner-Lambert Company Llc Isobutilgaba y sus derivados para el tratamiento del dolor
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2003250481A1 (en) * 2002-08-15 2004-03-03 Pfizer Inc. Therapeutic use of fused bicyclic or tricyclic amino acids
AU2003303040B2 (en) * 2002-12-13 2009-04-23 Warner-Lambert Company Llc Pregabalin derivatives for the treatment of fibromyalgia and other disorders
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR20050084445A (ko) * 2002-12-20 2005-08-26 다이노젠 파마세우티컬스, 인코포레이티드 α₂δ 서브유닛 칼슘 채널 모듈레이터를 이용한 무통증방광 질환의 치료방법
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
DE602004024317D1 (de) * 2003-09-12 2010-01-07 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
MXPA06003725A (es) * 2003-10-08 2006-06-23 Mallinckrodt Inc Solucion de fenidato de metilo y metodos asociados de administracion y produccion.
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
EP1543831A1 (de) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Zusammensetzung enthaltend Pregabalin
DE102004015752B4 (de) * 2004-03-31 2007-04-05 Christian-Albrechts-Universität Zu Kiel Verwendung von Gabapentin-Laktam zur Behandlung renaler Erkrankungen
WO2006041158A1 (ja) * 2004-10-14 2006-04-20 Daikin Industries, Ltd. 雰囲気改変方法、並びに、それに用いられる噴霧剤及び噴霧装置
US20100144681A1 (en) * 2005-08-11 2010-06-10 Klaus Fuchs Compounds for the treatment of alzheimer's disease
WO2007017510A2 (de) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Isophthalsäurediamide zur behandlung der alzheimer erkrankung
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
SG176464A1 (en) * 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2246044A1 (de) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Kinderärztliche Lösungen für Betablocker
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) * 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
WO2015144825A1 (en) * 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
CN104940930A (zh) * 2015-05-31 2015-09-30 黑龙江佰彤儿童药物研究有限公司 一种治疗儿童癫痫药物口服乳剂及其制备方法
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
US11738020B2 (en) 2018-08-18 2023-08-29 Ftf Pharma Private Limited Stable liquid vigabatrin pharmaceutical composition for oral dosage
EP3836899A2 (de) * 2018-08-18 2021-06-23 FTF Pharma Private Limited Chemotherapeutische pharmazeutische suspension zur oralen verabreichung
GB2591396B (en) 2018-08-18 2023-06-07 Ftf Pharma Private Ltd Pharmaceutical suspension for oral dosage
CA3131336A1 (en) * 2019-03-26 2020-10-01 Mirja Huhtinen Pregabalin formulations and use thereof
HU231397B1 (hu) 2021-01-22 2023-06-28 Egis Gyógyszergyár Zrt. Pregabalint tartalmazó topikális gyógyszerkészítmény
EP4281061A4 (de) 2021-01-22 2025-01-22 Egis Gyógyszergyár Zrt. Dispergiertes pregabalin enthaltende topische formulierung
WO2022168968A1 (ja) * 2021-02-05 2022-08-11 学校法人近畿大学 末梢神経障害の予防又は改善剤
US20250127739A1 (en) * 2021-08-31 2025-04-24 Avion Phamaceuticals, LLC Stable gabapentin powder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
WO1999059573A1 (en) * 1998-05-15 1999-11-25 Warner-Lambert Company Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
CZ20031399A3 (cs) * 2000-11-30 2004-04-14 Pfizer Products Inc. Farmaceutický prostředek, kterým je směs agonistů gama-aminomáselné kyseliny a inhibitorů sorbitoldehydrogenázy

Also Published As

Publication number Publication date
SI1395242T1 (en) 2006-10-31
NZ529173A (en) 2005-07-29
PL366384A1 (en) 2005-01-24
DE60213592D1 (de) 2006-09-14
CA2446574A1 (en) 2002-11-28
KR100582963B1 (ko) 2006-05-24
ZA200308393B (en) 2005-04-26
CR7150A (es) 2004-02-23
SK286227B6 (sk) 2008-05-06
US20020198261A1 (en) 2002-12-26
JP2004534764A (ja) 2004-11-18
BR0209973A (pt) 2004-04-06
EG24078A (en) 2008-05-11
HRP20030833A2 (en) 2004-08-31
CY1105147T1 (el) 2010-03-03
GEP20053620B (en) 2005-09-26
IS2428B (is) 2008-10-15
IL158359A0 (en) 2004-05-12
IS6986A (is) 2003-10-09
EE200300587A (et) 2004-02-16
PA8545901A1 (es) 2003-09-05
HRP20030833B1 (en) 2007-04-30
US20040072904A1 (en) 2004-04-15
CN100346779C (zh) 2007-11-07
AP1815A (en) 2008-01-04
EA008087B1 (ru) 2007-02-27
MXPA03009392A (es) 2004-01-29
PT1395242E (pt) 2006-11-30
KR20040003006A (ko) 2004-01-07
BG108376A (bg) 2005-04-30
AP2003002907A0 (en) 2003-12-31
PE20030087A1 (es) 2003-02-14
HK1062646A1 (zh) 2004-11-19
EP1395242B1 (de) 2006-08-02
SK14112003A3 (sk) 2004-08-03
RS87203A (sr) 2006-10-27
US7256216B2 (en) 2007-08-14
HUP0401366A2 (hu) 2004-11-29
AR033922A1 (es) 2004-01-07
CZ299755B6 (cs) 2008-11-12
EA200301152A1 (ru) 2004-04-29
DE60213592T2 (de) 2007-08-09
NO20035200L (no) 2003-11-24
CN1509165A (zh) 2004-06-30
SV2003001053A (es) 2003-03-18
WO2002094220A1 (en) 2002-11-28
ES2265040T3 (es) 2007-02-01
MY128615A (en) 2007-02-28
EP1395242A1 (de) 2004-03-10
CA2446574C (en) 2008-04-01
OA12604A (en) 2006-06-08
CZ20033066A3 (cs) 2004-08-18
DK1395242T3 (da) 2006-10-30
DOP2002000403A (es) 2002-11-30
NO20035200D0 (no) 2003-11-24
AU2002258026B2 (en) 2007-08-02
MA27026A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
ATE334656T1 (de) Flüssige pharmazeutische zusammensetzung
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
DE60127002D1 (de) Pharmazeutische zusammensetzung
FI20011478L (fi) Farmaseuttinen koostumus
NO20033384L (no) Farmasoytisk formulering
PL367180A1 (pl) Trwała kompozycja farmaceutyczna
ATE320244T1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
DE602004016967D1 (de) Flüssige pharmazeutische palonosetronformulierungen
ATE320807T1 (de) Pharmazeutische zusammensetzungen enthaltend tegaserod
NO20035627D0 (no) Farmasöytisk formulering
FI20022128L (fi) Farmaseuttinen koostumus
ATE324883T1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
ATE366128T1 (de) Pharmazeutische zusammensetzung
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
DE10107261B4 (de) Pharmazeutische Zusammensetzung
EP1413314A4 (de) Medizinische zusammensetzungen
NO20041236L (no) Farmasoytisk formulering
FI5468U1 (fi) Farmaseuttinen koostumus
SE0103565D0 (sv) Pharmaceutical formulation
SE0102572D0 (sv) Pharmaceutical formulation
SE0102957D0 (sv) Pharmaceutical formulation
SE0101326D0 (sv) Pharmaceutical formulation
SE0101325D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1395242

Country of ref document: EP

REN Ceased due to non-payment of the annual fee